Quantitative Investment Management LLC Purchases New Holdings in Synopsys, Inc. $SNPS

Quantitative Investment Management LLC acquired a new stake in shares of Synopsys, Inc. (NASDAQ:SNPS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,219 shares of the semiconductor company’s stock, valued at approximately $3,068,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Invesco Ltd. increased its holdings in shares of Synopsys by 17.2% in the third quarter. Invesco Ltd. now owns 1,885,761 shares of the semiconductor company’s stock valued at $930,416,000 after purchasing an additional 276,983 shares during the period. Seven Mile Advisory acquired a new stake in shares of Synopsys during the third quarter worth $220,000. Sei Investments Co. lifted its holdings in shares of Synopsys by 88.0% during the third quarter. Sei Investments Co. now owns 535,270 shares of the semiconductor company’s stock worth $264,095,000 after purchasing an additional 250,500 shares during the period. Douglass Winthrop Advisors LLC grew its position in Synopsys by 2.7% in the 3rd quarter. Douglass Winthrop Advisors LLC now owns 12,497 shares of the semiconductor company’s stock valued at $6,166,000 after buying an additional 323 shares during the last quarter. Finally, BOKF NA grew its position in Synopsys by 8.0% in the 3rd quarter. BOKF NA now owns 1,259 shares of the semiconductor company’s stock valued at $621,000 after buying an additional 93 shares during the last quarter. 85.47% of the stock is owned by institutional investors and hedge funds.

More Synopsys News

Here are the key news stories impacting Synopsys this week:

• Positive Sentiment: Launched hardware-assisted verification (HAV) upgrades and new platforms that target AI chip verification, promising up to 2x performance/capacity improvements for emulation and prototyping — a direct revenue opportunity as AI chip complexity increases. Synopsys Introduces Software-Defined Hardware-Assisted Verification
• Positive Sentiment: Unveiled new software tools and integrated solutions for designing AI chips and systems (first wave after the Ansys deal), which reinforce Synopsys’ market leadership in EDA for AI and could accelerate cross‑sell of Ansys capabilities. Synopsys rolls out new software tools for designing AI chips (Reuters)
• Positive Sentiment: Launched Ansys 2026 R1 and announced integrated Synopsys‑Ansys workflows (multiphysics + simulation + AI features), which expand addressable markets and product stickiness for system‑level design workflows. Synopsys Launches Ansys 2026 R1
• Positive Sentiment: Introduced the Electronics Digital Twin (eDT) Platform targeting automotive software validation and digital twin workflows — a strategic move into automotive software and systems markets. Synopsys eDT Platform Opens New Automotive Software Growth Question
• Neutral Sentiment: CEO Sassine Ghazi outlined a “silicon-to-systems” vision at Synopsys Converge 2026 and showcased multiple product roadmaps — important for long-term strategy but not an immediate revenue event. Synopsys Outlines Vision for Engineering the Future
• Neutral Sentiment: Coverage and note pieces (Zacks, TipRanks, Yahoo) highlight Synopsys as a trending/buy candidate and recap the new product slate — these raise visibility but leave valuation and timing questions open. Is Trending Stock Synopsys, Inc. (SNPS) a Buy Now?
• Negative Sentiment: Valuation/near-term performance concerns: market notes and analyses point to stalled share performance over recent months, mixed sentiment about how quickly the Ansys acquisition will convert to revenue, and an elevated P/E (background), which can prompt profit‑taking despite new product news. Synopsys (SNPS) Valuation Check As Shares Stall And Ansys Deal Reshapes Growth Story

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Needham & Company LLC restated a “buy” rating on shares of Synopsys in a research report on Thursday, February 26th. The Goldman Sachs Group set a $600.00 target price on shares of Synopsys and gave the company a “buy” rating in a report on Wednesday, February 25th. Citigroup began coverage on shares of Synopsys in a research note on Monday, November 24th. They set a “buy” rating and a $580.00 price target on the stock. Bank of America raised shares of Synopsys from an “underperform” rating to a “neutral” rating and cut their price target for the stock from $525.00 to $500.00 in a report on Monday, December 8th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $480.00 price objective (down from $550.00) on shares of Synopsys in a research report on Wednesday, February 25th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $531.00.

Insider Transactions at Synopsys

In other Synopsys news, CFO Shelagh Glaser sold 3,657 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $460.77, for a total value of $1,685,035.89. Following the completion of the transaction, the chief financial officer directly owned 17,842 shares of the company’s stock, valued at approximately $8,221,058.34. This trade represents a 17.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Janet Lee sold 250 shares of Synopsys stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $530.00, for a total transaction of $132,500.00. Following the sale, the insider owned 11,959 shares of the company’s stock, valued at approximately $6,338,270. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 4,157 shares of company stock worth $1,945,036. 0.56% of the stock is owned by insiders.

Synopsys Price Performance

Synopsys stock opened at $418.72 on Friday. The company has a market cap of $80.21 billion, a P/E ratio of 65.02, a price-to-earnings-growth ratio of 3.53 and a beta of 1.15. Synopsys, Inc. has a one year low of $365.74 and a one year high of $651.73. The business has a fifty day moving average of $463.28 and a two-hundred day moving average of $465.85. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.26 and a current ratio of 1.36.

Synopsys (NASDAQ:SNPS) last posted its quarterly earnings results on Wednesday, February 25th. The semiconductor company reported $3.77 earnings per share for the quarter, topping analysts’ consensus estimates of $3.56 by $0.21. The business had revenue of $2.41 billion for the quarter, compared to analysts’ expectations of $2.39 billion. Synopsys had a net margin of 13.76% and a return on equity of 6.83%. The business’s revenue for the quarter was up 65.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.03 EPS. Synopsys has set its FY 2026 guidance at 14.380-14.460 EPS and its Q2 2026 guidance at 3.110-3.170 EPS. As a group, analysts predict that Synopsys, Inc. will post 10.64 earnings per share for the current fiscal year.

Synopsys Profile

Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.

In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.